US 2014/0024597 A1Published application

Intranasal delivery of cell permeant therapeutics

AssigneeThe Trustees of Columbia University in the City of New York

InventorsCarol M. Troy, Nsikan Akpan, Guy Salvesen, Scott Snipes

Life of this patent

Estimating the term…

Abstract

The present invention relates to compositions and methods for the inhibition of apoptosis associated with ischemic injury in the central nervous system. In addition, the present invention relates to compositions and methods useful for extending the therapeutic window associated with ischemic injury.

Claims18

Dependent claims

A method of treating ischemic injury in the central nervous system comprising intranasally administering an effective amount of an apoptotic target inhibitor to a subject in need thereof, where said ischemic injury is treated thereby.

Dependencies are inferred from the claim text.

Facts

Application: 13/768,687Filed 15 Feb 2013
Priority: 16 Aug 2010
Published: 23 Jan 2014
Term ends: Not estimatedThe source records don’t support an estimate.

Classification15 codes

A61K 38/16
Medicinal preparations containing peptides: peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
A61K 9/0043
Galenical forms characterised by the site of application: nose
A61K 38/4873
Acting on peptide bonds: cysteine endopeptidases , e.g. stem bromelain, papain, ficin, cathepsin H
A61K 38/55
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof: protease inhibitors

Family

Application61/374,113Us provisional application · filed 16 Aug 2010
Application13/768,687Continuation
US 2014/0024597 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results